Published in Gene Therapy Weekly, August 31st, 2000
"Utility of the alpha-fetoprotein (afp) promoter for gene therapy against hepatocellular carcinoma (HCC) is limited because of the weak promoter activity," stated G.W. Cao and colleagues, Nara Medical University, Japan. "To circumvent this, the 5.1-kb 5'-flanking sequence of the human afp gene including the entire enhancer and silencer regions as well as the promoter region was employed for achieving strong, HCC-selective transgene expression."
Cao et al. published the results of their study in the International...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly